In addition, biopharming offers tremendous flexibility and economy when adjustments in production are necessary.
Some of the demands of the Grocery Manufacturers of America and other food trade associations were reasonable, but not their recommendations to the FDA that food plants should be off limits for biopharming "unless the company developing the drug product clearly demonstrates that it is not feasible to use non-food crops" and that "land, labor and equipment [be] dedicated solely to growing" biopharmed products.
If regulation and other aspects of public policy don't unnecessarily inflate the costs of development, biopharming can revolutionize the pricing structure of many new drugs.
they have declined to establish non-zero tolerance levels for these substances, largely out of concern that opponents of biopharming would take advantage of such a move to proselytize against this new technology.
Like plant biotechnology, the development of biopharming requires productive public/private partnerships.
A strong motivation for support of biopharming is the prospect for economic development, but that goal has to stand up to other challenges.